Eric Glenn – Synergy Worldwide

Heart Institute – Clinical Trial Update using ProArgi-9 Plus

4/23/09

In response to continuous inquires regarding the study, I felt it appropriate to share a little of what we are seeing thus far… There is much excitement to report and while it would be inappropriate to get too in depth at this early stage, sharing a few highlights should be of value.

We are now at day 64 of the 90 day clinical trial for the first group of three groups that entered the trial in the week of February 2nd, 2009 and are now 2/3rds of the way through the initial trial while groups two and three are one week and two weeks behind respectively.

To set the stage for this update, it is important to remember that all of the participants were recruited from a “Congestive Heart Failure Clinic” and all had existing cardiovascular disease of significance. All patients were baseline tested using a multitude of diagnostic testing ranging from full blood profiles to testing with the latest in pulsewave technology to blood oxygen saturation levels. By using the wide range of diagnostic testing tools the results can be cross validated.

Trend #1 – Virtually all participants with elevated blood pressures have seen such significant reductions in B.P. that the attending physicians have begun down titrating (reducing strengths) their B.P. medications.

Trend #2 – Virtually all participants are seeing increased vessel function and blood flows.

Trend #3 - Many participants are making direct comments regarding their energy levels and tolerence of exercise.

Trend #4 – Virtually all participants that were suffering from diminished pulmonary (lung) function or blood oxygen saturation levels are seeing marked improvements resulting in significantly increased strength and endurance.

Below is a sneak peek into three individual participants experiences:

1) Female – morbidly obese- diabetic with significant vascular neuropathy and pain.

This patients pain greatly reduced within the first few weeks after beginning on the ProArgi-9 Plus. Unknown to the trial director her attending Endocrinologist mid-study changed her diabetic medication resulting in an increasing blood sugar level. The patient believing the increase was due to the ProArgi-9 Plus, without guidance from her physician, took herself off the ProArgi-9 Plus which caused a return of the vascular neuropathy pain within a few days. Upon discussing the event with the director of the study, the endocrinologist consulted with the patient and the diabetic medication was changed back to the orriginal prescription. After the blood sugars normalized, the patient once again began taking the ProArgi-9 Plus and within a few days the pain from the vascular neuropathy abated and of this date is non-existent.

2) Male significantly developed coronary heart disease with daily angina (heart pain)

This participant was using 6-12 nitroglycerin pills per day to address the blood flow constriction resulting in angina and is as of this date currently only using 1-3 nitroglycinerine pills per day.

3) Male significantly developed coronary heart disease with daily angina (heart pain)

This participant was using 4-9 nitroglycerin pills per day to address the blood flow constriction resulting in angina and as of this date has gone 3 weeks without the need of any nitroglycerine medications.

We expect to conclude the study as the 3rd group completes its 90 days the week of May 18th. It will take a couple of weeks to compile the data and another couple of weeks for a medical statistitician to analyze the data. This creates a mid June to early July data availability date.

When the repeat echocardiograms, Doppler tests, etc. (The CPW, supplied by Synergy Team Global, has also been used as one of the pieces of equipment for data.) are completed, there will be much to share and what we have all seen in small bits and pieces through our own personal experiences and that of our friend’s and family’s is now being medically documented. Needless to say, all involved are very pleased with the study. I personally feel very blessed to be able to represent a product that can make such profound differences in peoples health and quality of life.

While this study is being conducted on people with serious and in many cases “near-term life-threatening health conditions”, I think it is important to remember we have all seen and experienced ProArgi-9 Plus benefit us in everyday usage including those of us still blessed with good health.

 This report was authored by Dan SwinDell, Synergy Team Member